Summary of HTLV-I/II Antibody Reactivity in CD3-LDGL Patients*
. | . | HTLV Blot 2.3 . | ||||||
---|---|---|---|---|---|---|---|---|
. | . | . | . | . | . | |||
SERA . | env . | gag . | p21e . | Epitope . | Mapping . | |||
. | p21e . | gp46-I . | gp46-II . | p19 . | p24 . | GD21-1 . | GD21-2 . | BA-21 . |
1 | — | — | — | — | — | — | — | — |
2 | + | — | — | — | — | — | — | + |
3 | ++ | — | — | — | + | — | — | ++ |
4 | ++ | — | — | — | — | — | — | ++ |
5 | ± | — | — | — | — | — | — | + |
6 | + | — | — | + | + | — | — | + |
7 | — | — | — | — | — | — | — | — |
8 | + | — | — | — | — | — | — | + |
9 | + | — | + | ± | — | — | — | — |
10 | ++ | — | — | ± | — | — | — | ++ |
11 | — | — | — | ± | — | — | — | — |
12 | ++ | — | — | — | — | — | — | ++ |
13 | — | — | — | — | — | — | — | — |
14 | + | — | — | — | — | — | — | ++ |
15 | + | — | — | — | — | — | — | + |
. | . | HTLV Blot 2.3 . | ||||||
---|---|---|---|---|---|---|---|---|
. | . | . | . | . | . | |||
SERA . | env . | gag . | p21e . | Epitope . | Mapping . | |||
. | p21e . | gp46-I . | gp46-II . | p19 . | p24 . | GD21-1 . | GD21-2 . | BA-21 . |
1 | — | — | — | — | — | — | — | — |
2 | + | — | — | — | — | — | — | + |
3 | ++ | — | — | — | + | — | — | ++ |
4 | ++ | — | — | — | — | — | — | ++ |
5 | ± | — | — | — | — | — | — | + |
6 | + | — | — | + | + | — | — | + |
7 | — | — | — | — | — | — | — | — |
8 | + | — | — | — | — | — | — | + |
9 | + | — | + | ± | — | — | — | — |
10 | ++ | — | — | ± | — | — | — | ++ |
11 | — | — | — | ± | — | — | — | — |
12 | ++ | — | — | — | — | — | — | ++ |
13 | — | — | — | — | — | — | — | — |
14 | + | — | — | — | — | — | — | ++ |
15 | + | — | — | — | — | — | — | + |
Intensity of antibody reactivity is indicated by the following scale: — , no reactivity; ±, weak reactivity.
+, Moderate reactivity; ++, strong reactivity.